Identification of the First Selective Activin Receptor-Like Kinase 1 Inhibitor, a Reversible Version of L-783277.
Hanna ChoSandip SenguptaSean S H JeonWooyoung HurHwan Geun ChoiHong-Seog SeoByung Joo LeeJeong Hun KimMinhwan ChungNoo Li JeonNam Doo KimTaebo SimPublished in: Journal of medicinal chemistry (2017)
We synthesized 1 (San78-130), a reversible version of L-783277, as a selective and potent ALK1 inhibitor. Our study showed that 1 possesses great kinase selectivity against a panel of 342 kinases and more potent activity against ALK1 than L-783277. Among the six ALK isotypes (ALK1-6), ALK1 is most significantly inhibited by compound 1. Compound 1 suppresses the BMP9-induced Smad1/5 pathway by mainly inhibiting ALK1 in C2C12 cells. Our molecular dynamics simulations suggest that H-bonding interaction between the C-4' hydroxyl group of 1 and Arg334 of ALK1 substantially contributes to the ALK1 inhibition. To the best of our knowledge, 1 is the first selective ALK1 inhibitor. Furthermore, compound 1 promoted angiogenesis in both endothelial tube formation and microfluidic chip based 3D angiogenesis assays, suggesting that 1 could be a lead compound for therapeutic angiogenesis agents. Our study may provide an insight into designing selective and potent inhibitors against ALK1.
Keyphrases
- advanced non small cell lung cancer
- molecular dynamics simulations
- endothelial cells
- epidermal growth factor receptor
- high throughput
- vascular endothelial growth factor
- signaling pathway
- induced apoptosis
- epithelial mesenchymal transition
- oxidative stress
- wound healing
- high glucose
- tyrosine kinase
- cell cycle arrest
- drug induced
- binding protein